Metraipolis › archive › dc_db7f6c080c67
Paradoxical dominant negative activity of an immunodeficiency-associated activating PIK3R1 variant — Europe PMC PMID:39835783
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/39835783
- DOI
- 10.7554/elife.94420
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T13:46:25.685Z
- SHA-256 of the archived text
1a16a274008f81e20ff0999890be92ce44609ffe94b8ef52f7b50f8691d6bc1d- Stable URL of this page
https://metraipolis.com/documento/dc_db7f6c080c67
How to cite
Paradoxical dominant negative activity of an immunodeficiency-associated activating PIK3R1 variant — Europe PMC PMID:39835783 — Europe PMC (en), https://europepmc.org/article/MED/39835783 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_db7f6c080c67 (Metraipolis archive dc_db7f6c080c67, sha256 1a16a274008f81e20ff0999890be92ce44609ffe94b8ef52f7b50f8691d6bc1d)
BibTeX
@misc{dcdb7f6c080c67,
title = {Paradoxical dominant negative activity of an immunodeficiency-associated activating PIK3R1 variant — Europe PMC PMID:39835783},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/39835783},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_db7f6c080c67; sha256 1a16a274008f81e20ff0999890be92ce44609ffe94b8ef52f7b50f8691d6bc1d},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/39835783. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
PIK3R1 encodes three regulatory subunits of class IA phosphoinositide 3-kinase (PI3K), each associating with any of three catalytic subunits, namely p110α, p110β, or p110δ. Constitutional PIK3R1 mutations cause diseases with a genotype-phenotype relationship not yet fully explained: heterozygous loss-of-function mutations cause SHORT syndrome, featuring insulin resistance and short stature attributed to reduced p110α function, while heterozygous activating mutations cause immunodeficiency, attributed to p110δ activation and known as APDS2. Surprisingly, APDS2 patients do not show features of p110α hyperactivation, but do commonly have SHORT syndrome-like features, suggesting p110α hypofunction. We sought to investigate this. In dermal fibroblasts from an APDS2 patient, we found no increased PI3K signalling, with p110δ expression markedly reduced. In preadipocytes, the APDS2 variant was potently dominant negative, associating with Irs1 and Irs2 but failing to heterodimerise with p110α. This attenuation of p110α signalling by a p110δ-activating PIK3R1 variant potentially explains co-incidence of gain-of-function and loss-of-function PIK3R1 phenotypes. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: eLife, 2025 (prima pubblicazione 2025-01-21). Identificativi: PMID 39835783 · PMCID PMC11750134 · DOI 10.7554/elife.94420. Parole chiave degli autori: Human; Genetics; Mouse; Inflammation; Genomics; Insulin resistance; Immunodeficiency; Phosphoinositide 3-kinase; immunology; Pik3r1; Short Syndrome; Apds2. Descrittori MeSH principali: Immunologic Deficiency Syndromes; Growth Disorders; Class Ia Phosphatidylinositol 3-Kinase. Pagina: https://europepmc.org/article/MED/39835783 — https://doi.org/10.7554/elife.94420. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T12:00:49.513Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.